Apple Conference? Forget It. Biotech Is What Really Matters: StockTwits

NEW YORK (TheStreet) -- Apple  (AAPL) may be Monday's big newsmaker with its Worldwide Developer Conference. But traders on aren't waiting for Tim Cook and Co. to get started. Instead, they're watching announcements from small drug companies on medication trials and tuning in to rumors about big pharma buyouts.

And, so far today, their attention is paying off. 

The IBB Likely To Move Higher Along With These Biotechs With Catalysts Upcoming | $MNKD $OREX $IBB $BDSI #biotech

? Scott Matusow (@ScottMatusow) Jun. 2 at 08:58 AM

Drug companies Ariad Pharmaceuticals  (ARIA), MannKind (MNKD), NPS Pharmaceuticals  (NPSP) and Pharmacyclics  (PCYC) were the top trending tickers on Monday morning. They were joined on the trending bar of the dozen most discussed stocks by two biotech ETFs, iShares Nasdaq Biotechnology  (IBB) and SPDR S&P Biotech  (XBI).

Apple made the list too, due to hype over what management could reveal about the company's product pipeline and plans for Beats Electronics. But many on said that excitement was misplaced. Apple, they noted, has a history of disappointing WWDC expectations. The stock has declined after eleven of the past conferences.

$AAPL during WWDC , since 2003 & blog with details -> 11/11 losers for longs

? Kora Reddy (@paststat) Jun. 1 at 09:35 AM

Investors on StockTwits were most interested in Ariad Pharmaceuticals. The company topped the StockTwits trending ticker bar with news that a drug to treat certain types of gastrointestinal tumors had positive results in early Phase II clinical trials. The FDA is lifting a partial ban that had restricted the company's ability to enroll new human test subjects.

$ARIA ... this is positive news for "future" growth

? RoyalHouseOfRock (@RoyalHouseOfRock) Jun. 2 at 10:00 AM

MannKind shares rose nearly 3% ahead of the company's presentation at the Jefferies 2014 Global Health Care Conference, scheduled for today at 2:30 p.m. Investors hoped to hear positive news about Afrezza, MannKind's inhaled insulin treatment for diabetics.

$MNKD 4 hours left to the beginning of the conference.

? Donna Peran (@donnaperan) Jun. 2 at 10:20 AM

Afrezza is pending FDA-approval and was overwhelmingly recommended by an FDA subcommittee earlier this year, despite concerns about lung complications with the drug. Investors believe that the drug could take over the $45 billion diabetes-management market, as many diabetics would prefer a treatment that doesn't involve daily shots. Sentiment on the stock is 97% bullish, according to StockTwits analytics.

$MNKD added few more. Like the way she's holding. Expecting a strong action EOD

? Saif Ross (@Rossx) Jun. 2 at 10:24 AM

NPS Pharmaceuticals shares were up nearly 15% by 11 a.m. after a report in the Financial Times that Shire (SHPG) is considering acquiring the company. And investors on said shares should could climb higher than the $35.61 if rumors prove true that Shire secured a $5 billion credit facility to make a bid for the drug company, which focuses on treatments for people with rare disorders.

$NPSP (+21% pre) Shire said to have secured $5B credit facility for a takeover proposal to NPS Pharmaceuticals

? Open Outcrier (@openoutcrier) Jun. 2 at 09:09 AM

$NPSP 5B secured by Shire. Means 5B/106.33M O/S shares = $47.00 buyout price

? PR (@biotechwinner11) Jun. 2 at 07:53 AM

Pharmacyclics rose more than 2% after the company announced that its FDA-approved Imbruvica cancer drug boosted the survival rates of patients with leukemia or small lymphocytic lymphoma better than competing drugs. Patients who received the drug had a 78% reduction in the risk of cancer progression or death.

Sentiment on the stock was overwhelmingly bullish, with 89% of the crowd on StockTwits calling for gains, according to site analytics.

$PCYC This is a good stock to be in if you are not on a 1 - 2 day time horizon. Great data, FDA approved, sales ramping up.

? Christian Balmaceda (@balmacyclics) Jun. 2 at 10:40 AM

Risk is commercialization and potential competitors. That being said, Rx up and great data show Imbruvica can compete vs. Gild/Abbv.

? Christian Balmaceda (@balmacyclics) Jun. 2 at 10:43 AM

>>Read More: Krispy Kreme, Three Others Are Poised for More Volatility

>>Read More: Delta Boosts Order for the Newly Stylish Airbus A321

>>Read More: How to Trade Apple Ahead of Developer Conference, Stock Split

>>Read More: Coal Shares React Positively to EPA Emissions Rules

At the time of publication, the author held no positions in any of the stocks mentioned.

This article represents the opinion of a contributor and not necessarily that of TheStreet or its editorial staff.

More from Opinion

Red Hat CFO Tells TheStreet: Tech Trends Are Still in Our Favor

Red Hat CFO Tells TheStreet: Tech Trends Are Still in Our Favor

Throwback Thursday: Intel Edition

Throwback Thursday: Intel Edition

Intel's Next CEO Should Try Harder to Protect Its Flanks Against AMD and Others

Intel's Next CEO Should Try Harder to Protect Its Flanks Against AMD and Others

3 Warren Buffett Stock Picks That Could Be Perfect for Your Retirement Portfolio

3 Warren Buffett Stock Picks That Could Be Perfect for Your Retirement Portfolio

Wednesday Wrap-Up: GE and Facebook

Wednesday Wrap-Up: GE and Facebook